Clinical Study
Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience
Table 4
Tumor morphology, neoadjuvant therapy, tumor response to neoadjuvant therapy, HCC recurrence rate, and HCC recurrence related deaths.
| | Tumor morphology | Neoadjuvant therapy | Response | HCC recurrence | HCC recurrence related death | | Vital tumor remnants | Full-necrotic | No tumor detectable | No | Yes | No | Yes | Not specified |
| | No tumor | PEI | — | — | 2 100% | 2 100% | — | 2 100% | — | — | | TACE | — | — | 2 100% | 2 100% | — | 2 100% | — | — | | Surgery | — | — | 9 100% | 8 89% | 1 11% | 8 89% | 1 11% | — | | Surgery + TACE | — | — | 2 100% | 2 100% | — | 2 100% | — | — | | Surgery + TACE + CTX | — | — | 1 100% | 1 100% | — | 1 100% | — | — | | Overall | 0 | 0 | 16 | 15 | 1 | 15 | 1 | 0 |
| | Uninodular | None | 48 100% | — | — | 37 77% | 11 23% | 39 81% | 8 17% | 1 2% | | PEI | 22 73% | 8 27% | — | 25 83% | 5 17% | 25 83% | 4 13% | 1 3% | | TACE | 13 81% | 3 19% | — | 12 75% | 4 25% | 13 81% | 3 19% | — | | PEI + TACE | 6 75% | 2 25% | — | 7 88% | 1 13% | 8 100% | — | — | | Surgery | 3 75% | 1 25% | — | — | 4 100% | 2 50% | 2 50% | — | | CTX + TACE | 2 67% | 1 33% | — | 3 100% | — | 3 100% | — | — | | RFA | 2 100% | — | — | 2 100% | — | 2 100% | — | — | | RFA + TACE | — | 1 100% | — | 1 100% | — | 1 100% | — | — | | PEI + RFA | — | 1 100% | — | 1 100% | — | 1 100% | — | — | | Overall | 96 | 17 | 0 | 88 | 25 | 94 | 17 | 2 |
| | Multinodular, unilateral | None | 25 100% | — | — | 14 56% | 11 44% | 17 68% | 8 32% | — | | PEI | 5 83% | 1 17% | — | 6 100% | — | 6 100% | — | — | | TACE | 6 86% | 1 14% | — | 4 57% | 3 43% | 5 71% | 2 29% | — | | PEI + TACE | 4 100% | — | — | 4 100% | — | 4 100% | — | — | | Surgery | 3 100% | — | — | 1 33% | 2 67% | 2 67% | 1 33% | — | | CTX | 4 100% | — | — | 2 50% | 2 50% | 4 100% | — | — | | Surgery + TACE | 3 100% | — | — | 1 33% | 2 67% | 1 33% | 2 67% | — | | RFA | 3 100% | — | — | 2 67% | 1 33% | 2 67% | 1 33% | — | | Surgery + TACE + CTX | 1 100% | — | — | 1 100% | — | 1 100% | — | — | | RFA + TACE | 1 100% | — | — | 1 100% | — | 1 100% | — | — | | Overall | 55 | 2 | 0 | 36 | 21 | 43 | 14 | 0 |
| | Multinodular, bilateral | None | 34 100% | — | — | 12 35% | 22 65% | 15 44% | 19 56% | — | | PEI | 4 100% | — | — | 4 100% | — | 4 100% | — | — | | TACE | 7 100% | — | — | 2 29% | 5 71% | 2 29% | 5 71% | — | | PEI + TACE | 6 75% | 2 25% | — | 5 63% | 3 38% | 6 75% | 2 25% | — | | Surgery | 2 100% | — | — | — | 2 100% | — | 2 100% | — | | CTX | 2 100% | — | — | — | 2 100% | 1 50% | 1 50% | — | | Surgery + TACE | 2 100% | — | — | 1 50% | 1 50% | 1 50% | 1 50% | — | | Surgery + TACE + CTX | 3 100% | — | — | 3 100% | — | 3 100% | — | — | | Surgery + CTX | 1 100% | — | — | — | 1 100% | — | 1 100% | — | | PEI + RFA | 1 100% | — | — | — | 1 100% | 1 100% | — | — | | Surgery + PEI | 1 100% | — | — | — | 1 100% | 1 100% | — | — | | Overall | 63 | 2 | 0 | 27 | 38 | 34 | 31 | 0 |
| | Total | 214 | 21 | 16 | 166 | 85 | 186 | 63 | 2 |
|
|
